Analyst's OutlookAnalyst raises the price target for ARGX, maintaining a Buy rating, which signals confidence in the company's valuation and future performance.
Drug DevelopmentPipeline progress remains on track, with a Phase 3 trial for Vyvgart in TED expected to start, which is a key positive development.
Product DifferentiationVyvgart's pre-filled syringe provides additional differentiation from potential competitors, such as IMVT's IMVT-1402.